At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
Bevacizumab +1 moredrug
Likely dose
Bevacizumab 10 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Dacarbazine With the Anti-Vascular Endothelial Growth Factor Antibody (Bevacizumab) in Patients With Unresectable/Metastatic Melanoma
In Brief
A Phase 2 clinical trial evaluating Bevacizumab and Dacarbazine for Malignant Melanoma. Completed, enrolled 40 participants across 1 site.
Detailed Summary
This study will assess the preliminary anti-tumor activity and safety profile of a combination of bevacizumab and dacarbazine in participants with unresectable/metastatic melanoma not previously treated with chemotherapy for metastatic disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Melanoma
CountriesItaly
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
First PostedJul 2010
Primary CompletionMay 2012
TodayJul 2026
First PostedJul 16, 2010
Enrollment StartJun 30, 2006
Primary CompletionMay 31, 2012
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 16.0 years ago
Interventions
Bevacizumabdrug
Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Days 1 and 14 of each 28-day cycle.
Dacarbazinedrug
Dacarbazine will be given as 800 milligrams per square meter (mg/m\^2) via IV infusion on Day 1 of each 28-day cycle.